<DOC>
	<DOCNO>NCT01395797</DOCNO>
	<brief_summary>The goal propose research improve effectiveness treatment opioid nicotine dependence test novel pharmacological strategy . Specifically , pioglitazone , peroxisome proliferator-activated gamma receptor ( PPARÎ³ ) agonist , use adjunct agonist-based treatment .</brief_summary>
	<brief_title>Pioglitazone Heroin Nicotine Dependence</brief_title>
	<detailed_description>Although treatment opioid nicotine dependence exist , medication universally effective many patient unable stop use relapse rapidly , suggest treatment single agent alone insufficient facilitate cessation use many patient . Targeting additional pathway may contribute maintenance drug-taking behavior relapse may effective strategy treat individual resistant first-line approach .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Heroin</mesh_term>
	<criteria>2155 year age Physically healthy Able perform study procedure Pregnancy Physical dependence drug besides caffeine , heroin nicotine</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>